Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Melanoma
Study Name
EA6141: Randomized Phase II/III study of Nivolumab + Ipilimumab + Sargramostim vs Nivolumab + Ipilimumab in patients with unresectable stage III or stage IV melanoma.
Principal Investigator
Gordan Srkalovic, MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT02339571?term=EA6141&rank=1
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance